$NMTR 🚨 About Larazotide Acetate🚨 In celiac disease, larazotide is the only drug which has successfully met its primary endpoint with statistical significance in a Phase 2b efficacy clinical trial (342 patients). Nearly 600 subjects have been exposed to larazotide in clinical trials, and a safety profile comparable to placebo has been demonstrated. Larazotide has received Fast Track designation from the FDA and is currently enrolling patients in late-stage clinical development for celiac disease.
1
6
6 Likes